Abstract
Purpose
Calcipotriol is a potent drug for topical treatment of psoriasis because it manages to inhibit keratinocyte proliferation. In the present study we investigated the effects of calcipotriol on gene expression in human keratinocytes in terms of mechanism of how calcipotriol decreases proliferation.
Materials and methods
Cell proliferation was analyzed by MTT assay. The differential display approach together with qPCR was used to assess the gene expression after treatment. In addition, Western immunoblotting revealed differences on the protein level. Finally, transfection of the KCs with specific small interfering RNA determined the genes necessary to inhibit proliferation.
Results
KCs proliferation was decreased in a concentration-dependent manner. Moreover, calcipotriol dowregulated the expression of two proliferation factors: early growth response-1 (EGR1) and polo-like kinase-2 (PLK2). The protein levels of EGR1 and PLK2 were also decreased. Specific siRNA against EGR1 and PLK2 in KCs resulted in marked reduction of EGR1 and PLK2 expression. In both cases, the reduction resolved in the decreased proliferation of KCs.
Conclusion
This study provides a new insight into how calcipotriol affects proliferation of keratinocytes by decreasing the expression of EGR1 and PLK2. Furthermore, the results offer groundwork for developing novel compounds for the treatment of hiperproliferative skin disorders like psoriasis.
Similar content being viewed by others
References
F. Chamian and J. G. Krueger. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr. Opin. Rheumatol. 16:331–337 (2004).
R. C. McKenzie and E. Sabin. Aberrant signalling and transcription factor activation as an explanation for the defective grown control and differentiation of keratinocytes in psoriasis: a hypothesis. Exp. Dermatol. 12:337–345 (2003).
M. C. Heng, M. K. Song, J. Harker, and M. K. Heng. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br. J. Dermatol. 143:937–949 (2000).
C. Johansen, K. Kragballe, M. Rasmussen, T. N. Dam, and L. Iversen. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. Br. J. Dermatol. 151:600–607 (2004).
C. Johansen, E. Flindt, K. Kragballe, J. Henningsen, M. Westergaard, K. Kristiansen, and L. Iversen. Inverse regulation of the nuclear factor-κB binding to the p53 and interleukin-8 êB response elements in lesional psoriatic skin. J. Invest. Dermatol. 124:1284–1292 (2005).
R. Zenz, R. Eferl, L. Kenner, L. Florin, L. Hummerich, D. Mehic, H. Scheuch, P. Angel, E. Tschachler, and E. F. Wagner. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437:369–375 (2005).
B. Staberg, J. Roed-Petersen, and T. Menne. Efficacy of topical treatment in psoriasis with MC903, a new vitamin D analogue. Acta Derm. Venereol. 69:147–150 (1989).
R. S. Kirsner and D. Federman. Treatment of psoriasis: role of calcipotriene. Am. Fam. Phys. 52:237–240, 243–244 (1995).
L. Binderup and E. Bramm. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem. Pharmacol. 37:889–895 (1988).
K. Kragballe and I. L. Wildfang. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch. Dermatol. Res. 282:164–167 (1990).
E. Lee, S. H. Jeon, J. Y. Yi, Y. J. Jin, and Y. S. Son. Calcipotriol inhibits autocrine phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem. Biophys. Res. Commun. 284:419–425 (2001).
P. Milde, U. Hauser, T. Simon, G. Mall, V. Ernst, M. R. Haussler, P. Frosch, and E. W. Rauterberg. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J. Invest. Dermatol. 97:230–239 (1991).
W. E. Stumpf, M. Sar, F. A. Reid, Y. Tanaka, and H. F. DeLuca. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary and parathyroid. Science 206:1189–1190 (1979).
P. Liang and A. B. Pardee. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967–971 (1992).
H. Takahashi, M. Ibe, M. Kinouchi, A. Ishida-Yamamoto, Y. Hashimoto, and H. Iizuka. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J. Dermatol. Sci. 31:21–28 (2003).
J. Romer, E. Hasseleager, P. L. Norby, T. Steiniche, J. T. Clausen, and K. Kragballe. Epidermal overexpression of interleukine-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine A or calcipotriol. J. Invest. Dermatol. 121:1306–1311 (2003).
K. Kaufmann and G. Thiel. Epidermal growth factor and thrombin induced proliferation of immortalized human keratinocytes is coupled to the synthesis of Egr-1, a zinc finger transcriptional regulator. J. Cell Biochem. 85:381–391 (2002).
A. Gashler and V. P. Sukhatme. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog. Nucleic Acid Res. Mol. Biol. 50:191–224 (1995).
L. M. Khachigian and T. Collins. Early growth response factor 1: a pleiotropic mediator of inducible gene expression. J. Mol. Med. 76:613–616 (1998).
J. Svaren, T. Ehrig, S. A. Abdulkadir, M. U. Ehrengruber, M. A. Watson, and J. Milbrandt. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J. Biol. Chem. 275:38524–38531 (2000).
V. Chaturvedi, M. Cesnjaj, P. Bacon, J. Panella, D. Choubey, M. O. Diaz, and B. J. Nickoloff. Role of INK4a/Arf locus-encoded senescent checkpoints activated in normal and psoriatic keratinocytes. Am. J. Pathol. 162:161–170 (2003).
E. S. Silverman and T. Collins. Pathways of Egr-1-mediated gene transcription in vascular biology. Am. J. Pathol. 154:665–670 (1999).
S. Xie, B. Xie, M. Y. Lee, and W. Dai. Regulation of cell cycle checkpoints by polo-like kinases. Oncogene 24:277–286 (2005).
D. L. Simmons, B. G. Neel, R. Stevens, G. Evett, and R. L. Erikson. Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol. Cell Biol. 12:4164–4169 (1992).
S. Ma, J. Charron, and R. L. Erikson. Role of Plk2 (Snk) in mouse development and cell proliferation. Mol. Cell Biol. 23:6936–6943 (2003).
T. F. Burns, P. W. Fei, K. A. Scata, D. T. Dicker, and P. W. S. El Deiry. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells. Mol. Cell Biol. 23:5556–5571 (2003).
S. Warnke, S. Kemmler, R. S. Hames, H. L. Tsai, U. Hoffmann-Rohrer, A. M. Fry, and I. Hoffmann. Polo-like kinase-2 is required for centriole duplication in mammalian cells. Curr. Biol. 14:1200–1207 (2004).
V. Baron, E. D. Adamson, A. Calogero, G. Ragona, and D. Mercola. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 13:115–124 (2006).
K. Kaufmann, K. Bach, and G. Thiel. Extracellular signal-regulated protein kinases Erk1/Erk2 stimulate expression and biological activity of the transcription regulator Egr-1. Biol. Chem. 382:1077–1081 (2001).
J. Zuber, O. I. Tchernitsa, B. Hinzmann, A. C. Schmitz, M. Grips, M. Hellriegel, C. Sers, A. Rosenthal, and R. Schafer. A genome-wide survey of RAS transformation targets. Nat. Genet. 24:144–152 (2000).
Acknowledgements
The authors wish to express their appreciation to Professor Roger Pain for critical review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kristl, J., Slanc, P., Krašna, M. et al. Calcipotriol Affects Keratinocyte Proliferation by Decreasing Expression of Early Growth Response-1 and Polo-like Kinase-2. Pharm Res 25, 521–529 (2008). https://doi.org/10.1007/s11095-007-9388-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-007-9388-z